Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy

Table 1 General characteristics

Characteristics	2010-2014, 154 patients	2015-2019, 174 patients	All patients, 328
Sex, n (%)
Male	122 (79)	133 (76)	255 (78)
Female	32 (21)	41 (24)	73 (22)
Age in yr, mean ± SD
At diagnosis	67.6 ± 11.8	70 ± 10.7	68.9 ± 11.3
At death	69.7 ± 12.2a	72.4 ± 10.5a	71 ± 11.4
Etiology, n (%)
HCV	65 (42)	70 (40)	135 (41)
HBV	10 (6)	5 (3)	15 (5)
Alcoholic	18 (12)	40 (23)	58 (18)
Multiple etiology1	16 (10)	20 (11)	36 (11)
NAFLD	5 (3)	2 (1)	7 (2)
Hereditary hemochromatosis	0 (0)	4 (2)	4 (1)
Unknown/idiopathic	40 (26)	33 (19)	73 (22)

^aP < 0.05.

¹Viral and alcoholic. HBV: Hepatitis B virus; HCV: Hepatitis C virus; NAFLD: Nonalcoholic fatty liver disease; SD: Standard deviation.

Table 2 Tumor and clinical characteristics

Characteristics	2010-2014, 154 patients	2015-2019, 174 patients	All patients, 328
BCLC stage, n (%)
BCLC 0	4 (3)	8 (5)	12 (4)
BCLC A	47 (31)	58 (33)	105 (32)
BCLC B	31 (20)	43 (25)	74 (23)
BCLC C	56 (36)	57 (33)	113 (34)
BCLC D	16 (10)	8 (5)	24 (7)
Child-Pugh stage, n (%)
Class A	114 (74)	133 (76)	247 (75)
Class B	30 (19)	38 (22)	68 (21)
Class C	10 (6)	3 (2)	13 (4)
MELD score, mean ± SD	10.7 ± 3.8	10.4 ± 3.6	10.4 ± 3.6
Nodule characteristics, n (%)
Unifocal	65 (42)	75 (43)	140 (43)
Paucifocal	24 (16)	40 (23)	64 (20)
Multifocal	52 (34)	40 (23)	92 (28)
Infiltrative/massive	13 (8)	19 (11)	32 (10)
Dimension in cm, mean ± SD	4.3 ± 2.9	4.9 ± 3.3	4.6 ± 3.1

BCLC: Barcelona Clinic Liver Cancer; MELD: Model for end-stage liver disease; SD: Standard deviation.

Table 3 Therapies used

Therapy	2010-2014, 154 patients	2015-2019, 174 patients	All patients, 328
Surgical resection	3 (2)	5 (3)	8 (2)
Percutaneous radiofrequency ablation	31 (20)	25 (14)	56 (17)
TACE	58 (38)	66 (38)	124 (38)
SIRT	13 (8)	33 (19)	46 (14)
Sorafenib	11 (7)	6 (3)	17 (5)
Palliation	38 (25)	39 (22)	77 (23)

Data are n (%). SIRT: Selective internal radiation therapy; TACE: Trans-arterial chemo embolization.